Mealey's (October 15, 2018, 1:25 PM EDT) -- WASHINGTON, D.C. — On the same day it affirmed a Delaware federal judge’s determination of invalidity with regard to four patents covering the multiple sclerosis drug Copaxone, the Federal Circuit U.S. Court of Appeals on Oct. 12 also upheld an identical conclusion reached by the Patent Trial and Appeal Board with regard to three of the same patents, but based upon different prior art (Yeda Research and Development Co. Ltd. v. Mylan Pharmaceuticals Inc., et al., Nos. 2017-1594, -1595, -1596, Fed. Cir.. 2018 U.S. App. LEXIS 28750)....